ABSTRACT
Drug-eluting stents (DES) have revolutionized interventional cardiology, significantly reducing restenosis, one of the most difficult obstacles that remain in treating obstructive coronary disease.1-3 This is one of a handful of technologies that has achieved greater efficacy without increased risk to the patient. The enthusiasm with which this technology was anticipated, and subsequently embraced, has been tempered only by the significant increase in cost.
